Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*
The DOI matches its Crossref record.
Abstract
We have administered to 29 patients with macroprolactinoma the dopamine agonists bromocriptine and lisuride for 1-50 months (mean +/- SE, 12.7 +/- 1.8) in order to assess the effects of these drugs on tumor size. Fourteen patients were treated with bromocriptine (dose range, 7.5-20 mg/day), 12 patients were treated with lisuride (0.6-2 mg/day), and 3 patients were given both drugs. Computed tomography performed before and during treatment showed the occurrence of tumor shrinkage in 18 patients (62%), but in no case was a complete disappearance of the tumor observed. In 5 of these patients, it was even possible to document tumor shrinkage within the first month of treatment with low doses of the dopamine agonists, whereas in other patients, tumors shrank only after prolonged treatment with higher doses. Visual field and acuity improved or normalized in 8 of the 13 patients with visual defects; in some cases, the improvement was reported as early as 2 days after the treatment was started. Plasma PRL levels fell in all patients who showed a reduction in tumor size; in 2 other patients, PRL levels were only poorly suppressed, and tumor size remained unchanged. In the remaining patients, PRL levels were lowered without convincing evidence of tumor shrinkage. In considering the high percentage of patients showing tumor shrinkage under medical treatment, we propose a course with dopamine agonists as the first step in the management of patients with macroprolactinomas regardless of the presence of visual impairments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas
ARAFAH, B. M. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-6-1173 · Cited by 293
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
Greenman, Y., Tordjman, K., Kisch, E., Razon, N., Ouaknine, G., & Stern, N. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.5.7745003 · Cited by 74
Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function
WARFIELD, A., FINKEL, D. M., SCHATZ, N. J., SAVINO, P. J., & SNYDER, P. J. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-6-783 · Cited by 47
Metadata
- Authors
- CHIODINI, P., LIUZZI, A., COZZI, R., VERDEXS, G., OPPIZZI, G., DALLABONZANA, D., SPELTA, B., SILVESTRINI, F., BORGHI, G., LUCCARELLI, G., RAINER, E., & HOROWSKI, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1981-10
- Volume
- 53
- Issue
- 4
- Pages
- 737-743
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2081972040
- Cited by
- 142
- References
- 0
- FWCI
- 13.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*. https://app.cochat.ai/papers/10.1210/jcem-53-4-737
- The paper
- CHIODINI, P., LIUZZI, A., COZZI, R., VERDEXS, G., OPPIZZI, G., DALLABONZANA, D., SPELTA, B., SILVESTRINI, F., BORGHI, G., LUCCARELLI, G., RAINER, E., & HOROWSKI, R. (1981). Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem-53-4-737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.